Welcome to WordPress. This is your first post. Edit or delete it, then start writing! SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA)
– Phase 1 clinical trial expected to begin in Q1 2021 – Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to
Aurigene will be attending 2017 MassBio Annual Meeting, scheduled to be held on March 30-31, 2017 at Boston, Massachusetts. For more details about the conference, please click here
Aurigene will be attending 2017 American Academy of Dermatology Annual Meeting, scheduled to be held on March 03-07, 2017 at Orlando, Florida. For more details about the conference, please click
Aurigene a discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases, announced today the nomination of the development candidate and exercising of the option
